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ABSTRACT
With improvements in the treatment of children with sickle cell disease (SCD), there has been a significant
increase in the number of patients with SCD in adult hematology practice. Quality of life and life expectancy
continue to be severely compromised in adult patients; hydroxyurea is the only treatment currently available
that could reduce the severity and frequency of painful episodes. Allogeneic stem cell transplantation (SCT)
has been offered to children with SCD as a curative option. We discuss the implications of new developments
in the field of allogeneic SCT in the treatment of adult SCD patients in light of the experience derived from
pediatric transplantation. These developments include innovations in the conditioning regimens, GVHD
prophylaxis, and alternative donor SCT and their possible effect on adult SCD patients. Finally, we discuss a
nonmyeloablative conditioning protocol for adult SCD patients and the eligibility criteria for adult SCD
patients undergoing allogeneic transplantation.
© 2004 American Society for Blood and Marrow Transplantation
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pICKLE CELL DISEASE IN ADULTS
The last few decades have witnessed a signiﬁcant
mprovement in the management of sickle cell disease
SCD) in early childhood; 85% of the SCD patients
urvived beyond 20 years of age in the Cooperative
tudy of Sickle Cell Disease (CSSCD) cohort of
orth America [1]. Improved survival of children with
CD has resulted in a substantial increase in the num-
er of patients with SCD in adult hematology prac-
ice. However, in a recent prospective survey of the
atients in CSSCD who survived beyond 20 years, the
edian age at death was 42 years for men and 48 years
or women, implying a 25- to 30-year reduction in life
xpectancy compared with the general black popula-
ion [2]. More importantly, most deaths were related
o SCD. In contrast to the younger cohort in CSSCD,
n which the mortality peaked in the ﬁrst few years of
ife and was mostly due to infections, the causes of h
B&MTeath in the adult population were less predictable
2,3]. Overt organ failure was the cause of mortality in
8%, and another 33% died of acute painful crises,
ostly acute chest syndrome [2]. The mortality
ended to increase sharply every decade after 20 years.
These ﬁndings have serious implications in the
reatment of adult SCD patients. The clinical course
ften worsens in adulthood, even if symptoms were
ild and organ functions were optimum in childhood.
hronic organ damage is often not evident before the
hird or fourth decades of life. Acute crises are less
ell tolerated in the face of ongoing insidious vascular
amage to vital organs. Treatment of adult SCD pa-
ients is further complicated by lack of compliance
ith long-term drugs such as penicillin and hydroxy-
rea, overuse of narcotics and dependence, loss of
roductivity, and psychological symptoms in adult-
ood.
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2Hydroxyurea has been effective in reducing pain-
ul crises in adult SCD patients and thereby reducing
ospitalization and mortality [4]. However, its poten-
ial for reducing chronic organ damage is unclear.
oreover, protracted treatment with hydroxyurea is
ssociated with poor compliance. There has been little
rogress in the treatment of these patients that could
top or reverse the underlying process and result in
mprovement of survival and quality of life. Currently,
he only curative option for patients with SCD is
llogeneic stem cell transplantation (SCT). In the fol-
owing sections, we discuss the evolution of transplan-
ation in children with SCD and how we could explore
he new developments in allogeneic transplantation to
he beneﬁt of adult SCD patients in light of the
ediatric experience.
LLOGENEIC SCT FOR SCD
The ﬁrst report on cure of SCD was in a patient
ho underwent bone marrow transplantation (BMT)
or acute myeloid leukemia [5]. Since then, more than
60 patients have undergone transplantation for SCD,
ut this has been performed almost exclusively in
atients younger than 16 years old who have severe
anifestations of SCD. Table 1 summarizes the re-
ults of allogeneic transplantation reported by 3 major
roups [6-8]. Even though the more severely affected
atients underwent allogeneic transplantation, the
verall survival was 90% to 94%. The disease-free
urvival varied between 82% and 84%. Secondary
raft rejection and disease relapse occurred in 10% to
5% of patients. However, with additional immuno-
uppression, the problem of graft rejection was mini-
ized. Graft-versus-host disease (GVHD), both acute
nd chronic, although observed in a much smaller
roportion of patients than in comparable age groups
able 1. Results of Conventional Allogeneic Transplantation for Sickle
ell Disease in Children
Variable
Belgian [7]
(n  50)
French [8]
(n  60)
United States
[6] (n  59)
edian age, y (range) 8 (1.7-23) 8.8 (2.2-22) 10.1 (3.3-15.9)
raft rejection/disease
recurrence 10% 6.6% 9%
cute GVHD grade
I-II 38% NA 4%
cute GVHD grade
III-IV 2% 6.6% 3.8%
hronic GVHD 20% NA 4%
table mixed
chimerism 12% NA 22%
verall survival 93% 90% 93%
vent-free survival 82% 82% 84%
A indicates not applicable.ho underwent transplantation for malignant dis- h
4ases, has been the most signiﬁcant complication and
ause of death after allogeneic transplantation.
A unique posttransplantation problem encoun-
ered in SCD patients has been an increased incidence
f neurologic complications in the early posttrans-
lantation period, particularly in patients with prior
troke [9]. The most common neurological complica-
ions were intracranial hemorrhage and seizures.
owever, with prolonged anticonvulsant prophylaxis,
trict control of hypertension, prompt magnesium
upplementation, maintenance of higher hemoglobin
nd platelet count, and avoidance of cyclosporine tox-
city, these complications have been substantially re-
uced [6].
All patients with stable engraftment had a com-
lete resolution of sickle-related symptoms (anemia,
ainful crises, acute chest syndrome, and stroke). Ce-
ebral magnetic resonance imaging showed stable and
ven improved results [6]. Pulmonary functions were
lso stable or improved [6]. Growth and splenic func-
ion had also improved in those not receiving heavy
mmunosuppression for GVHD [6,7]. The major con-
ern has been the effect of conditioning regimens on
onadal functions. The follow-up has not been long
nough in most studies to evaluate the late effects,
uch as secondary malignancies, except for the Belgian
tudy, which reported 1 case of acute myelogenous
eukemia 4 years after transplantation [7].
However, despite the success of allogeneic BMT
n the phenotypic cure of SCD in children, the pro-
edure has not been advocated for adult SCD patients.
n the following sections, we raise the possibility and
nvestigate the prospects of using allogeneic SCT in
dults in the light of several observations made in the
ediatric population and the recent developments in
he ﬁeld of allogeneic transplantation.
EASIBILITY OF ALLOGENEIC TRANSPLANTATION IN
DULT SCD PATIENTS
A previous study indicated that approximately
8% of patients with SCD would have an unaffected
LA-identical sibling, but taking into account the
ligibility criteria and parental consent, only 1% to
% of the total population of SCD patients would
ndergo an allogeneic transplantation as a child [10].
hus, there would be a proportion of adult SCD
atients with potential family donors who did not
ndergo transplantation as children because of either
arental refusal or a failure to meet the eligibility
riteria [10,11]. The question remains as to whether
hese patients should be offered an allogeneic trans-
lantation and, if so, what the eligibility criteria and
he modality of transplantation should be.
A few patients older than 16 years (up to 23 years)
ave undergone allogeneic BMT in France and Bel-
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Allogeneic Transplantation for Adults with Sickle Cell Disease
Bium, and the effect of age was not discernible because
f extremely small numbers [7,8]. However, the adult
linical trial of the Seattle consortium was halted be-
ause of toxic death in the ﬁrst 2 patients [12]. Adult
atients with SCD are more likely to have chronic
ascular damage to vital organs such as kidneys, lungs,
rain, and heart and would thus be less likely to
olerate full-intensity conditioning. Concerns about
he feasibility of conventional conditioning in adult
CD patients raises issues about the timing of trans-
lantation and the modality.
HE RATIONALE FOR NONMYELOABLATIVE
ONDITIONING
Animal studies have demonstrated the feasibility
f achieving durable engraftment with a reduction in
he intensity of the conditioning if adequate immuno-
uppression is used [13]. Subsequent clinical trials in
hich nonmyeloablative conditioning was able to induce
table engraftment in patients with advanced malignan-
ies otherwise deemed unsuitable for full-intensity
onditioning have substantiated the concept [13-16].
Adult patients with SCD are less likely to with-
tand full-intensity conditioning because of the under-
ying incipient organ damage inﬂicted by the vascular
amage and the inﬂammatory state. If the transplant-
elated mortality in children is considered to be 5% to
0%, in adults, after conventional conditioning with
usulphan and cyclophosphamide, transplant-related
ortality is likely to increase severalfold. The other
onsiderations are rejection and GVHD. Because of
ultiple transfusions, these patients are more likely to
xperience graft rejection, which was exempliﬁed by
ejection in 4 of 12 patients in the French study who
ere conditioned without antithymocyte globulin
ATG) [8]. Patients with SCD have an underlying
nﬂammatory state, marked by the high circulating
evels of tumor necrosis factor- and endothelin-1
17], but whether that aggravates the host-versus-graft
eaction is not known. The high circulating levels of
umor necrosis factor- are likely to upregulate major
nd minor histocompatibility antigens, with an en-
anced recognition of these antigens by alloreactive T
ells, and thus increase the likelihood of severe
VHD [18]. Moreover, GVHD is an age-dependent
rocess and is likely to be a greater problem in adult
CD patients. Previous reports have suggested a
igher incidence of GVHD in the African-Caribbean
opulation, which could be due to a greater degree of
inor HLA antigen mismatch or a difference in the
harmacokinetics of anti-GVHD drugs [19,20].
IXED CHIMERISM AND SCD
Reduced-intensity conditioning was originally
roposed as a means of achieving mixed chimerism, h
B&MThich would allow stable engraftment and reduce the
ncidence of GVHD [13,15]. Mixed chimerism was
ocumented in several patients with SCD after con-
entional transplantation. In the multicenter study
rom the United States, stable mixed chimerism was
ocumented in 13 of 50 SCD patients with stable
ngraftment [21]. The level of donor chimerism var-
ed between 90% and 99% in 8 patients but was much
ower in 5 patients. The donor chimerism varied be-
ween 11% and 74% in these 5 patients, and even with
1% donor chimerism, the hemoglobin was stable and
he sickle cell hemoglobin (HbS) was only 7%. In the
elgian study, 3 of 50 patients had 10% host chi-
erism, and another 3 patients had 30%, 35%, and
0% host chimerism, all with normal hematology [7].
he conditioning regimens used in these studies were
ot designed to produce mixed chimerism, but mixed
himerism could have resulted from either a robust
ecipient immune system or in vivo T-cell depletion
f the graft by the circulating ATG that was used in
onditioning. Whatever the mechanism might be,
hese observations raise the possibility of phenotypic
ure of SCD by the induction of stable mixed hema-
opoietic chimerism.
However, these studies did not investigate lineage-
peciﬁc chimerism, and 2 recent murine studies have
acilitated our understanding of the chimerism of var-
ous lineages and cure of SCD. In lethally irradiated
ealthy mice, Iannone et al. [22] studied the effect of
econstitution with varying ratios of T cell–depleted
arrow from normal and transgenic sickle cell mice.
n their model, 25% normal myeloid chimerism re-
ulted in 90% normal hemoglobin in blood. Reduc-
ng the HbS levels to 80% resulted in progressive
ormalization in both hematologic and histologic pa-
ameters in a linear fashion until HbS reached 0%.
lthough 40% myeloid chimerism resulted in elimi-
ation of sickle red blood cells from circulation, 70%
himerism was required to eliminate anemia. Liver
nfarcts were observed with HbS of 16.8% even though
omplete hematologic correction was achieved. These
ndings suggest that mixed red blood cell chimerism
orrects hematologic indices but not organ pathology.
owever, the major caveat in interpreting these re-
ults is that the recipient mice lacked the sickle geno-
ype and could not be representative of the effects of
ixed chimerism in an SCD recipient.
Kean et al. [12] studied the effect of major histo-
ompatibility complex–mismatched T cell–depleted
MT in transgenic knockout sickle mice from
ALB/c and SJL mice with low-dose busulphan and
o-stimulation blockade of CD28/B7 and CD40/
D40L pathways. Ten of 13 mice achieved complete
ed blood cell chimerism and mixed white blood cell
himerism (43%) without developing GVHD; this
esulted in normalization of red cell morphology and
ematologic parameters and also of renal and spleen
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2athology. The higher level of donor red cells com-
ared with the white cells suggested a survival advan-
age of normal over sickle red blood cells. The survival
dvantage of normal red cells in SCD patients was
urther substantiated by the documentation of 10% to
4% red blood cell chimerism and 2.5% white cell
himerism in sickle mice conditioned without busul-
han. However, the murine models are unlikely to be
ully representative of the human SCD setting, par-
icularly when the mice were not presensitized by
revious transfusions, as would be the case with most
CD patients eligible for an allograft. There is little
oubt that engraftment across HLA barriers in mul-
iply-transfused adult SCD patients is likely to be
ore challenging.
The lesson we could derive from these studies is
hat red blood cell engraftment is essential for cure of
CD, which could be achieved with mixed lymphoid
r myeloid chimerism. The issue is whether we could
eliably induce mixed chimerism in a clinical setting
ith nonmyeloablative conditioning.
ESULTS OF NONMYELOABLATIVE TRANSPLANTATION
N SCD
Several anecdotal reports of nonmyeloablative
ransplantation for SCD have been published in the
ast couple of years that have included a few adult
atients. Table 2 summarizes these results. There
ave been 3 main approaches to nonmyeloablative
ransplantation. The Seattle group used low-dose total
ody irradiation (TBI) and a cyclosporine/mycophe-
olate-based approach in patients with advanced he-
atologic malignancies [13,14]; this resulted in suc-
essful engraftment in heavily pretreated patients, but
ot in others, such as those with chronic myeloid
eukemia. Contrary to the animal model, a reduced-
ntensity regimen failed to induce stable mixed chi-
erism [14]; however, it is worth noting that the
able 2. Nonmyeloablative Transplantation for Sickle Cell Disease
Variable
Iannone et al.
[23] (n  6)
van Besien e
[24] (n  2
onditioning Flu/200 cGy TBI/ATG
(n  2)
Flu/Mel/AT
ge, y 3 to 20 40 to 56
rimary engraftment 5 2
raft rejection/disease
recurrence
All None*
cute GVHD Grade II (n  1) Both
hronic GVHD None 1
table mixed chimerism Transient NA
eath/cause None GVHD (bot
lu indicates ﬂudarabine; TBI, total body irradiation; TLI, total l
phamide; ATG, antithymocyte globulin; NA, not applicable; G
Short follow-up or early death.nimals had a more robust immune system because of e
6he lack of any prior immunosuppression. This pro-
ocol has also been explored in SCD patients. The
ddition of ﬂudarabine, with or without ATG, to a
ow-dose TBI–based regimen failed to induce sus-
ained engraftment in 6 patients with SCD [23] (Table
). Tapering of posttransplantation immunosuppres-
ion was associated with a loss of donor graft in most
atients even 12 months after transplantation. How-
ver, the regimen was associated with no toxicity, and
he rejections were nonfatal with autologous reconsti-
ution after weaning of immunosuppression. The in-
eresting observations in this study were maintenance
f improved hematologic parameters and an HbS level
30%, despite the decline in donor chimerism
23,28]. In vitro studies on the posttransplantation
arrow samples demonstrated an overrepresentation
f donor erythroid progenitor cells over the myeloid
ounterpart, suggesting that the clinical beneﬁt from
ixed chimerism is derived both from an extended life
pan of mature donor red cells and a selective advan-
age of donor red cell progenitors in the marrow [28].
The other approach has been the combination of
udarabine and an alkylating agent with or without
TG or alemtuzumab (Campath-1H; Schering
ealth Care Ltd, West Sussex, UK) [15,16,29,30].
imilar to the experience with malignant diseases,
ost patients with SCD achieved sustained engraft-
ent after such conditioning regimens (Table 2). Use
f melphalan and ATG along with ﬂudarabine re-
ulted in sustained engraftment and cure in 2 adult
CD patients treated with this regimen, but both died
f GVHD [24]. The same group achieved successful
ngraftment without GVHD by replacing ATG with
lemtuzumab in a 24-year-old man [25]. The combi-
ation of ﬂudarabine, busulphan, ATG, and total lym-
hoid irradiation (500 cGy) was also successful in
chieving progressively improving donor chimerism
ithout GVHD in an 8-year-old girl at 14 months of
ollow-up [26]. A German group reported successful
van Besien et al.
[25] (n  2)
Krishnamurthi et al.
[26] (n  1)
Schleuning et al.
[27] (n  1)
Flu/Mel/alemtuzumab Flu/Bu/ATG/TLI Flu/Cyclo
19 and 24 8 22
2 1 1
1 No* No*
None No No
None No Yes
1 Yes Yes
None No No
id irradiation; Mel, melphalan; Bu, busulphan; Cyclo, cyclophos-
graft-versus-host disease.t al.
)
G
h)
ympho
VHD,ngraftment with limited chronic GVHD in a 22-
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Bear-old patient with 11 months of follow-up who had
nitial mixed chimerism that converted to full donor
himerism [27]. Although initial engraftment has been
easible with these protocols, the follow-up is too
hort to comment on sustained engraftment, given the
act that late graft rejections up to 6 to 12 months after
ransplantation have been documented in the low-
ose TBI protocol [23].
The third approach is aimed at reducing GVHD
y the use of in vitro T-cell depletion of the graft. In
itro T-cell depletion has resulted in a high incidence
f secondary graft failure in patients who have under-
one transplantation for malignant diseases with re-
uced-intensity conditioning [31,32]. However, if en-
raftment was sustained, stable mixed chimerism was
requently documented [32]. One patient with SCD
ho received in vitro T-cell depletion after reduced-
ntensity conditioning lost the graft by 28 days [25].
OW CAN WE SUCCESSFULLY DEVELOP A
ONMYELOABLATIVE CONDITIONING REGIMEN
OR ADULT SCD PATIENTS?
Limited experience with the 2 predominant ap-
roaches indicates that minimal conditioning based on
he Seattle protocol is unlikely to result in sustained
ngraftment in most adult SCD patients. However,
se of ﬂudarabine and an alkylating agent with or
ithout ATG could circumvent the problem of en-
raftment but cause an unacceptable degree of
VHD. Unlike with malignant diseases, an alloreac-
ive process is undesirable in SCD. GVHD is poorly
olerated by adult SCD patients, who already have
ustained serious compromise of organ functions.
hus, 2 issues need to be addressed to successfully
erform transplantation in an adult SCD patient.
irst, the conditioning should enable sustained en-
raftment, and GVHD should be minimal or absent.
ixed myeloid and lymphoid chimerism at an early
osttransplantation period is desirable. The murine
tudies and the early data from the Seattle group
uggest that erythroid lineage is likely to engraft faster
nd more completely than the myeloid lineage
12,28]. Early erythroid engraftment, on one hand,
elps in the rapid amelioration of sickle-related prob-
ems, and, on the other hand, mixed lymphoid chi-
erism at an early posttransplantation period is likely
o prevent the development of severe GVHD. Unfor-
unately, most of the existent nonmyeloablative pro-
ocols are associated with unstable chimerism that
ither rapidly converts to full donor chimerism with a
igh incidence of GVHD or loses donor cells with
utologous reconstitution [14-16].
In the United Kingdom, the use of a regimen
onsisting of alemtuzumab in vivo has resulted in a
ery low incidence of GVHD, with sustained engraft- o
B&MTent in almost all patients [30]. Sustained mixed chi-
erism was documented in approximately 30% of the
atients [33]. The major problems associated with this
rotocol have been a delayed immune reconstitution,
hich increased the susceptibility to viral infections,
nd a lack of early graft-versus-leukemia effect in
igh-risk malignancies [34]. The delayed immune re-
onstitution observed in that study [34] was attributed
o the prolonged half-life of alemtuzumab, which not
nly results in depletion of T cells of the infused graft,
ut also hampers the early lymphocyte recovery [35].
dose de-escalation study on alemtuzumab is cur-
ently under way to determine the right balance be-
ween immune reconstitution and prevention of
VHD. The only other protocol that has been asso-
iated with a low incidence of GVHD has been a
ombination of ﬂudarabine and cyclophosphamide,
nd this has been a consistent ﬁnding in both clinical
nd experimental studies [29,36].
Ideally, T-cell depletion of the graft is the most
eliable method for prevention of GVHD. In SCD, in
itro T-cell depletion will signiﬁcantly increase the
robability of graft rejection. How best to balance the
egree of host immunosuppression and the extent of
-cell depletion in the setting of nonmyeloablative
ransplantations is currently unclear. The Pessaro
roup [37] has achieved successful engraftment in
dult thalassemic patients with ﬂudarabine and re-
uced doses of busulphan and cyclophosphamide, pre-
eded by preconditioning with hydroxyurea and aza-
hioprine. In 14 adult thalassemic patients treated with
his protocol, the overall survival was 70% and event-
ree survival was 57%.
We propose to incorporate all 3 of these elements
nto our suggested conditioning protocol for adult
CD patients. The conditioning protocol would in-
orporate ﬂudarabine 30 mg/m2 for 5 days, cyclophos-
hamide 30 mg/kg for 2 days, and alemtuzumab 60
g over 3 days from day 6 to day 4, preceded by
ydroxyurea 1 to 2 g/d and azathioprine 50 to 100 mg
aily for 6 weeks. The preferred choice would be
ranulocyte colony-stimulating factor–stimulated pe-
ipheral blood stem cells from a HLA-matched family
onor with a target dose of 5  106 CD34 cells per
ilogram. However, it needs to be borne in mind that
ny reduced-intensity protocol will have to go
hrough phase I trials in adult SCD patients and that
ny experimental protocol should not be used outside
he framework of a clinical trial.
Fertility is a major issue in patients with SCD. To
ake the nonmyeloablative protocol acceptable to
dult SCD patients, the effect of the conditioning
rotocol on fertility should be carefully considered
nd studied. We expect the proposed protocol to have
ess of an effect on gonadal function than busulphan-
r melphalan-containing protocols.
27
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2ATIENT SELECTION
If we consider allogeneic transplantation to be a
urative option for SCD, it should be offered to all
illing patients. However, the main problem with the
pproach is the fact that a signiﬁcant proportion of
atients would be exposed to the morbidity and mor-
ality currently associated with the procedure. It can-
ot be assumed, unless proven, that a particular non-
yeloablative regimen will be associated with less
oxicity than conventional transplantation. Thus, the
ligibility criteria for allogeneic transplantation with
educed-intensity conditioning needs to be outlined
ith a degree of rigorousness essential for clinical
rials. Although such guidelines exist for pediatric
ransplantation, it is more difﬁcult to identify a suit-
ble adult population that is likely to beneﬁt from an
llogeneic transplantation with low regimen-related
oxicity.
It is also important to be aware of the perception,
xpectation, and acceptance of such procedures in the
atient group. A survey was performed on 100 adult
CD patients in Chicago to assess the their perception
f allogeneic transplantation, by using a standard ref-
rence gamble paradigm [38]. Twenty-eight patients
ere unwilling to accept any risk of short-term mor-
ality to be cured of SCD. Sixty-three patients were
illing to accept a risk of short-term mortality of
5%. Of these patients, 20 patients were ready to
ccept a risk 30%, and 12 patients were willing to
ccept a risk of 40%. More importantly, there was a
ack of concordance between the willingness of health-
are providers to offer an allogeneic transplantation
nd the patients’ decisions. Acceptance of a high-risk
urative option might differ according to the health-
are system and the perceptions in a given community.
e are currently undertaking a similar survey at our
enter to determine the patient-related factors and the
roportion of adult patients with possible matched
amily donors. Our current recommendations for in-
lusion in the reduced-intensity allogeneic transplan-
ation trial are detailed in Table 3.
IMING OF TRANSPLANTATION: EARLIER RATHER
HAN LATER
The clinical trials investigating the role of alloge-
eic SCT in SCD have included only patients with
ore severe disease. However, the Belgian study in-
luded 14 asymptomatic or minimally symptomatic
atients in their study, with the argument that they
ere to return to their country of origin where the
upportive care was not optimal [7]. The outcome in
his group of patients was remarkable, with 100%
verall survival, 93% event-free survival, and no in-
tance of grade III or IV acute or extensive chronic
VHD. The popular concept that allogeneic trans- d
8lantation is too toxic to be offered to less symptom-
tic patients is challenged by these ﬁndings. There is
ittle doubt that if the preexisting organ damage and
nderlying inﬂammation are minimal, the probabili-
ies of conditioning-related toxicity, rejection, and
VHD would be reduced. If transplantation is being
onsidered for an adult SCD patient, these factors
hould be prime considerations. These patients have
lready been subjected to 2 decades of insidious or
bvious organ damage, which is reﬂected in the sharp
ncrease in mortality every decade after 20 years and
hich is often compounded by long-term blood trans-
usion and resultant iron overload [39]. Allogeneic
ransplantation is more likely to be successful if it is
onsidered earlier than later, and the eligibility criteria
n adult patients should be sought in a different setting
han children with SCD.
LTERNATIVE DONOR TRANSPLANTATION
One of the major barriers to the development of
llogeneic transplantation in SCD is the lack of fully
atched family donors in most [10,11]. The major
hallenge lies in the development of alternative donor
ransplantation if most SCD patients are to beneﬁt
rom an allogeneic transplantation.
Unrelated donor (UD) bone marrow or peripheral
lood transplantation has been developed as an effec-
ive alternative to family donor grafts for the treat-
ent of hematologic malignancies, but not for
onmalignant disorders or hemoglobinopathies, in
articular. Recently, the Pessaro group [40] demon-
trated that with extended haplotype matching, the
utcome of UD transplantation in patients with
halassemia can be signiﬁcantly improved. However,
he major problem in developing a UD transplant
rogram is an underrepresentation of the ethnic
roups with SCD in the national and international
able 3. Proposed Eligibility Criteria of Adult SCD Patients for
onmyeloablative Transplantation
Patients with matched family donors without major
hemoglobinopathy; age <40 y; with one or more of the
following despite treatment with hydroxyurea:
More than 3 hospital admissions with painful crises in 1 y
Chronic severe debilitating pain from SCD
More than 1 episode of acute chest syndrome in 2 y
History of stroke or neurologic event lasting >24 h
Refractory leg ulcers
Early evidence of organ damage (eg, renal, pulmonary, or
cardiac)
Transfusion dependence
Without evidence of
End-stage pulmonary or renal disease
HIV infection
Other irreversible comorbid condition
IV indicates human immunodeﬁciency virus.onor registries.
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Allogeneic Transplantation for Adults with Sickle Cell Disease
BUD cord blood might be a more readily available
ource of stem cells for SCD patients. Initial results of
elated cord blood transplantation in children with
CD are extremely encouraging [41]. The Eurocord
ransplant group reported the outcome of 33 patients
ith thalassemia and 11 patients with SCD who re-
eived related cord blood transplantation (median age
f all patients, 5 years; range, 1-20 years). At a median
ollow-up of 24 months, the overall survival in both
isease groups was 100%, with 90% disease-free sur-
ival in SCD patients (1/11 SCD patients rejected the
raft). The probability of developing acute and
hronic GVHD in all patients was 11% and 6%,
espectively. The immunologic naivety of cord blood
ells could be advantageous when HLA-mismatched
ransplantation is considered. However, the major
roblem in adult transplantation is obtaining the op-
imum stem cell dose, given the overriding impor-
ance of cell dose in achieving engraftment [42]. It is
orth noting that in the Eurocord study, a high cell
ose was obtained (median, 4  107/kg; range, 1.2-
0  107/kg), which might not be a consistent feature
f unrelated cord units. In this study, the use of meth-
trexate in GVHD prophylaxis adversely affected
vent-free survival. A major impediment in developing
nrelated cord blood transplantation for adult SCD
atients is a greater likelihood of rejection for grafts
ith a lower cell dose and fewer alloimmune T cells
ue to a stronger host-versus-graft effect, as discussed
reviously.
The most readily available donor in any disease
ondition is usually an HLA haplotype-mismatched
elative, generally a parent or sibling. Considering the
aucity of matched related donors for patients with
CD and the poor availability of suitable UDs from
egistries, a mismatched family donor is the best op-
ion for an adult SCD patient in terms of availability.
he recent developments in the ﬁeld of haplotype-
ismatched transplantation have been a landmark in
he evolution of allogeneic transplantation [43]. The
erugia group [43] has demonstrated that successful
ngraftment could be achieved if the donor was con-
itioned with ﬂudarabine, thiotepa, total body radia-
ion, or melphalan and ATG. CD34 selected grafts
ontaining megadoses of CD34 cells resulted in an
lmost complete absence of GVHD. However, the
ajor problem has been a signiﬁcant delay in immune
econstitution and resulting fatal infections. More-
ver, adult SCD patients are unlikely to tolerate such
ntensive conditioning. The same investigators have
urther explored the role of natural killer cell alloreac-
ivity in engraftment and survival [44]. In murine
odels, natural killer cell infusion has resulted in
ustained engraftment with minimal conditioning
45]. The detrimental effects of extensive T-cell de-
letion might be overcome by infusion of antigen-
peciﬁc T cells [46,47] or l-leucyl-l-leucine methyl u
B&MTster–treated T cells, which prevents GVHD by de-
leting dipeptidyl peptidase I–expressing cytotoxic
ellular subsets, yet preserves the response to recall
ntigens [48]. A recent report from a Japanese group
uggested that engraftment with an acceptable degree
f GVHD can be achieved without T-cell depletion if
he haploidentical donor is the mother or a noninher-
ted maternal antigen–mismatched sibling, on the ba-
is of the concept of tolerance developed because of
etomaternal chimerism [49]. Although it is possible
hat the limited diversity of HLA antigens in the
apanese population might have a favorable inﬂuence
n the outcome of such transplantations, this concept,
f proven to be clinically viable in larger studies in
ther populations, may circumvent many problems
ssociated with T cell–depleted haploidentical grafts.
Several other approaches of reducing GVHD and
et achieving engraftment and maintaining the reac-
ivity of T cells to third-party antigens are currently
eing explored. Additional co-stimulatory signals are
equired for sustained T-cell activation, and blocking
o-stimulatory signals have been evaluated as potential
easures to reduce GVHD [49]. The administration
f CTLA4 immunoglobulin or anti-CD28 antibodies,
hich block the interaction of CD28 on T cells and
7 molecules on antigen-presenting cells, and anti-
D40L (CD154) monoclonal antibody, which can
nterfere with the interaction of CD154 on T cells and
D40 on antigen-presenting cells, has been shown to
educe the severity of GVHD in animal models
50,51]. Guinan et al. [52] reported successful engraft-
ent with a low incidence of GVHD after infusion of
aploidentical donor bone marrow incubated with
TLA4 immunoglobulin. Thus, blockade of co-stim-
lation pathways provides a potential for inducing
nergy and reducing GVHD without T-cell deple-
ion, yet retaining a normal antigenic response. The
se of mesenchymal cells [53] and keratinocyte growth
actors [54] has been shown to reduce GVHD, pro-
ote engraftment, and reduce conditioning-related
issue damage in preclinical and phase I studies.
ONCLUSION
The major obstacles to the development of allo-
eneic transplantation for SCD are the paucity of
atched family donors and the morbidity and mor-
ality associated with the procedure. If engraftment
nd stable mixed chimerism can be induced by re-
uced-intensity conditioning, their combination may
igniﬁcantly reduce conditioning-associated toxicity
nd GVHD and result in cure of sickle-related symp-
oms. Limited experience of reduced-intensity condi-
ioning in SCD patients has been dismal. The best
ay to achieve stable mixed chimerism is currently
nclear, and clinical trials are ongoing. Attempts to
29
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3ncrease the ethnic representation in the UD registries
nd similar clinical trials on UD bone marrow and
ord blood transplantation are warranted. Further de-
elopments in the ﬁeld of haploidentical donor trans-
lantation might offer the best chance of cure for most
atients with SCD.
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